Source link : https://www.newshealth.biz/health-news/growing-price-tag-reported-for-newer-de-facto-stroke-lytic/
NEW ORLEANS — Tenecteplase in recent years outpaced alteplase as the stroke thrombolytic of choice at one large hospital system, despite shrinking cost savings, a researcher reported here. In 2021, clinicians at Cardinal Health-managed and consulting hospitals used alteplase almost exclusively for acute ischemic stroke. But the tide turned to tenecteplase from 2022 to 2024 […]
Author : News Health
Publish date : 2024-12-12 22:42:32
Copyright for syndicated content belongs to the linked Source.
Categories